Related Experiment Videos
SELECT: the selenium and vitamin E cancer prevention trial
Eric A Klein1, Ian M Thompson, Scott M Lippman
1Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA. kleine@ccf.org
Urologic Oncology
|April 10, 2003
Summary
This study investigated if selenium and vitamin E reduce prostate cancer risk in men. Results are pending, but preclinical data suggest potential benefits for cancer prevention.
Area of Science:
- Oncology
- Nutritional Science
- Preventive Medicine
Background:
- Emerging evidence suggests selenium and vitamin E may lower prostate cancer risk.
- Prostate cancer remains a significant health concern for men worldwide.
Purpose of the Study:
- To evaluate the efficacy of selenium and vitamin E in preventing prostate cancer.
- The SELECT trial is a randomized, prospective, double-blind study in healthy men.
Main Methods:
- Review of preclinical and epidemiological data on selenium and vitamin E chemoprevention.
- Inclusion of secondary analyses from existing randomized trials.
- Development of the SELECT study schema based on prior evidence and trials.
Main Results:
- Preclinical, epidemiological, and Phase III data indicate potential efficacy of selenium and vitamin E for prostate cancer prevention.
- The Prostate Cancer Prevention Trial and SELECT's early enrollment highlight men's commitment to cancer prevention studies.
- SELECT plans to randomize 32,400 men.
Conclusions:
- SELECT is a major large-scale study on prostate cancer chemoprevention.
- Enrollment commenced in 2001, with results expected in 2013.